FY 2024 (No.409-)
| Issue |
No. |
Table of contents |
| September 2024 |
413 |
Full text [406 KB]
|
| August 2024 |
412 |
Full text [356 KB]
- Article 1. How to Start and Proceed With Improving Polypharmacy Among the Elderly in Regions
- Article 2. Important Safety Information
Article 2.-1 Epoprostenol sodium
Article 2.-2 [1] Nivolumab (genetical recombination), [2] Ipilimumab (genetical recombination)
Article 2.-3 Tirabrutinib hydrochloride
Article 2.-4 Gadobutrol
- Article 3. Revisions of PRECAUTIONS (No.352)
Article 3.-1 Freeze-dried smallpox vaccine prepared in cell culture (and 7 others)
- Article 4. List of Products Subject to Early Post-marketing Phase Vigilance
|
| July 2024 |
411 |
Full text [389 KB]
- Article 1. Revisions of PRECAUTIONS for Preparations Containing Brimonidine Tartrate
- Article 2. Recent Efforts on MID-NET
- Article 3. Important Safety Information
Article 3.-1
[1] Brimonidine tartrate
[2] Brimonidine tartrate/timolol maleate
[3] Brimonidine tartrate/brinzolamide
[4] Ripasudil hydrochloride hydrate/brimonidine tartrate
- Article 4. Revisions of PRECAUTIONS (No.351)
Article 4.-1 Pembrolizumab (genetical recombination) (and 6 others)
- Article 5. List of Products Subject to Early Post-marketing Phase Vigilance
|
| June 2024 |
410 |
Full text [241 KB]
- Article 1. Drug-induced Enterocolitis Syndrome
- Article 2. Revisions of PRECAUTIONS (No. 350)
Article 2.-1 Rivaroxaban (and 4 others)
- Article 3. List of Products Subject to Early Post-marketing Phase Vigilance
|
| April 2024 |
409 |
Full text [1,009 KB]
- Article 1. Utilization of Risk Management Plan (RMP) in Clinical Settings
- Article 2. Revisions of PRECAUTIONS for Carvedilol and Bisoprolol
- Article 3. Important Safety Information
Article 3.-1 Andexanet alfa (genetical recombination)
- Article 4. Revisions of PRECAUTIONS (No.349)
Article 4.-1 Andexanet alfa (genetical recombination) (and 4 others)
|
